A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate Safety and tolerability of MASCT-I in patients with
advanced solid tumors, either alone or in combination with chemical drugs or in combination
with PD1 antibody.